pI: 8.6245 |
Length (AA): 227 |
MW (Da): 26069 |
Paralog Number:
2
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Ortholog group members (OG5_128350)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT5G03430 | phosphoadenosine phosphosulfate (PAPS) reductase family protein |
Babesia bovis | BBOV_I002340 | phosphoadenosine phosphosulfate reductase family domain containing protein |
Brugia malayi | Bm1_07710 | Probable molybdopterin binding domain containing protein |
Candida albicans | CaO19.12186 | Flavin adenine dinucleotide (FAD) synthetase |
Candida albicans | CaO19.4723 | Flavin adenine dinucleotide (FAD) synthetase |
Caenorhabditis elegans | CELE_R53.1 | Protein FLAD-1, isoform D |
Dictyostelium discoideum | DDB_G0282955 | hypothetical protein |
Drosophila melanogaster | Dmel_CG16848 | CG16848 gene product from transcript CG16848-RA |
Drosophila melanogaster | Dmel_CG4407 | CG4407 gene product from transcript CG4407-RA |
Echinococcus granulosus | EgrG_000242200 | fad synthase |
Echinococcus multilocularis | EmuJ_000242200 | fad synthase |
Giardia lamblia | GL50803_16269 | FAD synthetase |
Homo sapiens | ENSG00000160688 | flavin adenine dinucleotide synthetase 1 |
Leishmania braziliensis | LbrM.28.0280 | phosphoadenosine phosphosulfate reductase-like protein |
Leishmania donovani | LdBPK_280410.1 | phosphoadenosine phosphosulfate reductase-like protein |
Leishmania infantum | LinJ.28.0410 | phosphoadenosine phosphosulfate reductase-like protein |
Leishmania major | LmjF.28.0270 | phosphoadenosine phosphosulfate reductase-like protein |
Leishmania mexicana | LmxM.28.0270 | phosphoadenosine phosphosulfate reductase-like protein |
Loa Loa (eye worm) | LOAG_11838 | lenep protein |
Mus musculus | ENSMUSG00000042642 | RFad1, flavin adenine dinucleotide synthetase, homolog (yeast) |
Neospora caninum | NCLIV_051520 | DJ-1/PfpI family domian-containing protein, putative |
Oryza sativa | 4326240 | Os01g0259600 |
Plasmodium berghei | PBANKA_1213400 | FAD synthetase, putative |
Plasmodium falciparum | PF3D7_1015000 | FAD synthetase, putative |
Plasmodium knowlesi | PKNH_0815100 | FAD synthetase, putative |
Plasmodium vivax | PVX_094970 | FAD synthetase, putative |
Plasmodium yoelii | PY07439 | fad synthetase |
Saccharomyces cerevisiae | YDL045C | FMN adenylyltransferase |
Schistosoma japonicum | Sjp_0301520 | ko:K00953 FMN adenylyltransferase [EC2.7.7.2], putative |
Schistosoma mansoni | Smp_126650 | molybdopterin-binding |
Schmidtea mediterranea | mk4.007983.02 | |
Trypanosoma brucei gambiense | Tbg972.11.8490 | phosphoadenosine phosphosulfate reductase-like protein, putative |
Trypanosoma brucei | Tb927.11.7420 | phosphoadenosine phosphosulfate reductase-like protein |
Trypanosoma congolense | TcIL3000.11.8020 | phosphoadenosine phosphosulfate reductase-like protein |
Trypanosoma congolense | TcIL3000_0_31180 | phosphoadenosine phosphosulfate reductase-like protein |
Trypanosoma cruzi | TcCLB.511151.50 | phosphoadenosine phosphosulfate reductase-like protein, putative |
Trypanosoma cruzi | TcCLB.508241.60 | phosphoadenosine phosphosulfate reductase-like protein, putative |
Toxoplasma gondii | TGME49_214280 | phosphoadenosine phosphosulfate reductase family protein |
Theileria parva | TP03_0087 | FAD synthetase, putative |
Trichomonas vaginalis | TVAG_486660 | fad synthetase, putative |
Trichomonas vaginalis | TVAG_322610 | molybdopterin- binding protein, putative |
Trichomonas vaginalis | TVAG_166700 | fad synthetase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb11.02.5320 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb11.02.5320 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb11.02.5320 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb11.02.5320 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_R53.1 | Caenorhabditis elegans | slow growth | wormbase |
YDL045C | Saccharomyces cerevisiae | inviable | yeastgenome |
PBANKA_1213400 | Plasmodium berghei | Dispensable | plasmo |
TGME49_214280 | Toxoplasma gondii | Probably essential | sidik |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Hepatitis B virus | Core antigen | Compounds | References |